Raptor Pharmaceutical Corp Form 4

September 11, 2013 FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average burden hours per

0.5

response...

5. Relationship of Reporting Person(s) to

Issuer

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

Raptor Pharmaceutical Corp [RPTP]

Symbol

1(b).

(Print or Type Responses)

Daley Thomas E

1. Name and Address of Reporting Person *

| | | | Raptor | 1 marma | cutical C | (Check all applicable) | | |) | | |
|--|---|-------|----------|-----------------|---|------------------------|----------------------|--|--|---|--|
| | (First) OR CEUTICAL COI N LANDING, S | | | Day/Year) | Fransaction | | _ b | Director Officer (give ti | | Owner er (specify | |
| | (Street) | | 4. If Am | endment, I | Date Origina | al | 6 | . Individual or Join | nt/Group Filin | g(Check | |
| Filed(Month/Day/Year) NOVATO, CA 94949 | | | | | ear) | | _ | Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| (City) | (State) | (Zip) | Tab | ole I - Non | -Derivative | Secu | rities Acqui | red, Disposed of, | or Beneficiall | y Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Dat (Month/Day/Year) | | Date, if | Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or | | (D) 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| Common Stock | 09/09/2013(1) | | | Code V | Amount 5,000 | (D) | Price \$ 14.2412 (3) | 79,906 | D | | |
| Common Stock | 09/09/2013(1) | | | S | 5,000 | D | \$ 14.2427 (4) | 74,906 | D | | |
| Common Stock | 09/09/2013(1) | | | S | 5,000 | D | \$ 14.2371 (5) | 69,906 | D | | |

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

| Common Stock | 09/09/2013 <u>(1)</u> | M | 10,000 | A | \$ 2.23 (2) | 79,906 | D |
|-----------------|-----------------------|---|--------|---|----------------------|--------|---|
| Common Stock | 09/09/2013 <u>(1)</u> | S | 10,000 | D | \$ 14.3272 (6) | 69,906 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Date

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | /Day/Year) Execution Date, if TransactionDerivative any Code Securities (Month/Day/Year) (Instr. 8) Acquired (A or Disposed (D) | | Securities Acquired (A) or Disposed of | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount o Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|--------|--|--|--------------------|--|------------------------------------|
| | | | | Code V | and 5) (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Share |
| Stock options (right to | \$ 2.23 | 09/09/2013(1) | | M | 10,000 | 03/10/2008(2) | 09/10/2017 | Common Stock | 10,000 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | |
|--|---------------|-----------|---------|-----------------------------------|--|--|
| 1 | Director | 10% Owner | Officer | Other | | |
| Daley Thomas E C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO, CA 94949 | | | | President, Raptor Therapeutics | | |

Signatures

buy)

/s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp.,
Attorney-in-fact

09/11/2013

**Signature of Reporting Person

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 13, 2013.
- (2) Options were issued pursuant to the Issuers 2006 Equity Incentive Plan. Options vest 6/48ths on March 10, 2008 and 1/48th per month thereafter.
- This transaction was executed in multiple trades at prices ranging from \$14.07 to \$14.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$14.10 to \$14.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$14.10 to \$14.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$14.22 to \$14.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (7) The shares listed as owned in column 9 represents the total shares that remain outstanding for this option grant dated 9/10/2007.
- (8) Fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.